In cell cultures analyzed in the current study, hrsACE2 inhibited the coronavirus load by a factor of 1,000-5,000. Credit: IMBA/Tibor Kulcsar
Team designs antibody-like receptor proteins that can bind to cytokines, as possible strategy for treating coronavirus and other infections.
One of the defining features of Covid-19 is the excessive immune response that can occur in severe cases. This burst of immune overreaction, also called a cytokine storm, damages the lungs and can be fatal.
A team of MIT researchers has developed specialized proteins, similar in structure to antibodies, that they believe could soak up these excess cytokines.
“The idea is that they can be injected into the body and bind to the excessive cytokines as generated by the cytokine storm, removing the excessive cytokines and alleviating the symptoms from the infection,” says Rui Qing, an MIT research scientist who is one of the senior authors of the study.
The researchers have reported their initial findings in the journal Quarterly Review of Biophysics (QRB) Discovery, and they now hope to begin testing their proteins in human cells and in animal models of cytokine release and coronavirus infection.
Shuguang Zhang, a principal research scientist in the MIT Media Lab’s Laboratory of Molecular Architecture, is also a senior author of the paper. Shilei Hao, a visiting scientist at MIT, is the lead author of the study, and David Jin, CEO and president of Avalon GloboCare, is also an author.
A molecular sponge
The researchers’ work on blocking cytokine storms grew out of a project that Zhang began 10 years ago to develop modified versions of membrane-embedded proteins. These proteins are usually difficult to study because once they are extracted from the cell membrane, they only maintain their structure if they are suspended in special types of detergents.
After working on the problem for several years, Zhang and Qing developed a method for modifying the hydrophobic regions of these proteins, making them soluble in water and much easier to study. Their method, called the QTY code, calls for replacing some hydrophobic amino acids with hydrophilic amino acids that have similar structures. Leucine is converted to glutamine, isoleucine and valine are converted to threonine, and phenylalanine is converted to tyrosine.
Following the development of the QTY code, Jin approached Zhang’s lab with the idea of designing water-soluble versions of proteins known as cytokine receptors. These receptors are found on the surface of immune cells, where they bind to cytokines — signaling proteins that stimulate inflammation and other immune responses.
Jin believed that proteins that mimic these cytokine receptors could help combat cytokine storms, which can be produced by viral or bacterial infections, including HIV and hepatitis. They can also occur as a side effect of cancer immunotherapy.
In April 2019, Zhang’s team set out to design proteins that could sop up these excess cytokines like a sponge. To do that, they used the QTY code to make water-soluble versions of cytokine receptors. When proteins are soluble in water, they can travel efficiently through the human bloodstream, while the original, hydrophobic versions of the proteins would likely stick to cells that they encountered.
The researchers also attached an antibody segment called the Fc region to their water-soluble receptor proteins. This region helps to further stabilize the proteins in the bloodstream, and makes them less likely to be attacked by the immune system.
The researchers designed proteins that mimic six different cytokine receptors, which can bind to cytokines such as interferon and interleukin, as well as a class of cytokines called chemokines. In laboratory tests of the proteins’ binding strength, the researchers found that their modified proteins were able to bind to cytokines with similar strength as naturally occurring cytokine receptors.
“The cytokine receptors that we designed will soak up the majority of the excessive cytokines that are released during the cytokine storm,” Jin says.
Driven by curiosity
In March, when evidence began to suggest that the SARS-CoV-2 virus was inducing cytokine storms in some patients, the researchers realized that the receptor proteins they had designed might be able to help. They decided to quickly publish the results they have generated so far, and they are now planning to do additional tests in human cells and in animal models of Covid-19 infection.
The potential usefulness of this approach underscores the importance of “curiosity-driven research,” Zhang says.
“As it turns out, our research initiated in April 2019 is directly relevant to the treatment of Covid-19 infected patients,” he says. “Curiosity-driven, or even proactive research often leads to preparedness, which is key to preventing future disasters.”
The researchers have filed for patents on the proteins that they designed, as well as on their overall approach to creating water-soluble cytokine receptors. They hope to license the technology quickly and to collaborate with pharmaceutical and biotech companies who can help to move it toward clinical trials.
“Obviously this approach will need further animal studies, and potentially human clinical studies,” Jin says. “But we have confidence that this discovery will contribute to clinical applications to address viral diseases that involve cytokine storms.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Researchers discover new biomarker for severe Covid 19
There is also a need for improved diagnostics in COVID 19-patients," says Eduardo Cardenas, postdoc researcher at the Institute of Environmental Medicine, Karolinska Institutet, and principal author ...
- Researchers may have found a new biomarker for acute COVID-19
Researchers have shown that patients with acute COVID-19 infection have increased levels of the cytokine IL-26 in their blood. Moreover, high IL-26 levels correlate with an exaggerated inflammatory ...
- Cancer Therapy Deemed Safe for COVID-19 Patients Without Immunosuppression
In the absence of immunosuppression, systemic cancer therapies do not increase the risk of severe COVID-19 or cytokine storm, a study suggests.
- Cytokine Market To Be Valued at US$ 141,667.1 Mn at a CAGR of 8.9% By 2028 | Johnson & Johnson, Abbvie Inc., Sanofi SA, Pfizer Inc.
taNK, haNK, & t-haNK platforms have been made to state specific problems of T-cell treatment comprising the decrease of threat of severe cytokine storms. COVID-19 outbreak is anticipated to ...
- What is a subtropical storm and how is it different from a tropical or extratropical system?
A subtropical storm is what's known to forecasters as a "hybrid" storm, a meteorological mashup of a tropical and "extratropical" storm. Such a system, Subtropical Storm Nicole, formed in the ...
Go deeper with Google Headlines on:
[google_news title=”” keyword=”cytokine storms” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
- mRNA drugs with a built-in ‘copy machine’ could lead to safer, more effective therapies
Another one of the company’s oncology treatments encodes immune cytokines and proteins meant to make tumors more responsive to immune attacks. Your daily guide to what’s happening in biotech. Please ...
- Gut microbiome plays a role in Alzheimer's
In a recent review published in the journal Pharmacological Research, researchers in Brazil investigated the role of gut microbiota in cognition, brain function, behavior, and neurodegenerative ...
- Inflammation in Brain’s Immune Cells Triggers Depressive Behavior in Mice
New research into the neural mechanisms behind depression concludes that a protein complex called an inflammasome, which induces inflammation and often triggers cell death, may be a key player in the ...
- Study discovers that mitochondria transmit signals in the immune and nervous systems
Mitochondria are primarily known as the powerhouse of the cell. However, these cellular organelles are required not only for providing energy: Professor Konstanze Winklhofer and her group at the ...
- Peninsula biotech moves from layoffs to cancer-fighting deal with potential $2B payoff
CytomX Therapeutics Inc., which four months ago cut 40% of its staff after a clinical trial failure, said Thursday it snagged a $30 million upfront payment with a cancer drug research and development ...
Go deeper with Google Headlines on:
[google_news title=”” keyword=”cytokines” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]